文献速递类风湿关节炎其他结缔组织病

免疫检查点抑制剂相关炎症性关节炎

Immune Checkpoint Inhibitor-Associated Inflammatory Arthritis.
PubMed 文献 · Arthritis Rheumatol · 2026-04-20

本文综述免疫检查点抑制剂相关炎症性关节炎(ICI-IA)的临床与机制研究。ICI-IA 约发生于 6% 的 ICI 治疗患者,表型常类似类风湿关节炎但通常血清阴性;滑膜以 CD38hiCD127-CD8+ T 细胞克隆扩增及 IL-1βhi 巨噬细胞经 CXCL10-CXCR3 和 CCR1-CCL3/5 轴交互为特征。

要点

  • ICI-IA 约见于 6% 的 ICI 治疗患者,表型常类似类风湿关节炎但通常血清阴性。
  • 即使无关节肿胀,ICI 相关关节痛患者影像常显示关节炎症。
  • 联合 ICI 时初始 CD4+ T 细胞活化与 Treg 细胞受损起协同放大作用。

核心结论

  • ICI-IA 具有独特的滑膜免疫机制,可为理解其他类型炎症性关节炎的生物学与演变提供线索。

研究设计与样本

  • 本文为综述,总结当前对 ICI-IA 的认识并提出未来研究方向。

主要发现

  • ICI-IA 约发生于 6% 的 ICI 治疗患者,表型常类似类风湿关节炎但通常血清阴性。
  • ICI 相关关节痛患者影像常显示关节炎症,即使无关节肿胀。
  • ICI-IA 滑膜以活跃增殖的 CD38hiCD127-CD8+ T 细胞克隆扩增及 interleukin-1βhi 巨噬细胞扩增为特征。
  • 上述细胞沿 CXCL10-CXCR3 和 CCR1-CCL3/5 轴进行通讯。
  • 初始 CD4+ T 细胞活化与 Treg 细胞受损起协同放大作用,尤其在联合 ICI(抗 CTLA-4 联合抗 PD-1)时。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Understanding the cellular and molecular mechanisms of T cell activation has enabled the identification of immune checkpoints, such as programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and the development of immune checkpoint inhibitors (ICIs), which have revolutionized cancer therapy. However, ICI cancer treatment is commonly associated with autoimmune side effects, including inflammatory arthritis (IA). ICI-IA occurs in approximately 6% of ICI-treated patients and often resembles rheumatoid arthritis phenotypically, although it is generally seronegative. Imaging often demonstrates joint inflammation in patients with ICI-associated joint pain, even in the absence of joint swelling. The ICI-IA synovium is characterized by clonal expansion of actively proliferating CD38hiCD127-CD8+ T cells and expansion of interleukin-1βhi macrophages, communicating along CXCL10-CXCR3 and CCR1-CCL3/5 axes. Activation of naive CD4+ T cells and impaired Treg cells play a synergistic and amplifying role, especially in the setting of combination ICI (anti-CTLA-4 plus anti-PD-1). ICI-IA has the potential to teach us about mechanisms underlying the biology and evolution of other forms of IA. In this review, we summarize our current understanding of ICI-IA and propose promising avenues for future research.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Kim ST, Bass AR. Immune Checkpoint Inhibitor-Associated Inflammatory Arthritis. Arthritis Rheumatol. 2026. PMID: 41800958. doi:10.1002/art.70128

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。